Novartis to buy Anthos Therapeutics for up to $3.1B
Novartis (NYSE:NVS) to acquire Anthos Therapeutics for a total deal value of up to $3.1B, consisting of an upfront payment of $925M, with potential additional payments of up to $2.15B. Anthos ...
United Therapeutics scores FDA go-ahead for pig organ transplant clinical trial
United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...
MyChesCo on MSN5d
Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the completion of enrollment for its Explore-CKD Phase 2 trial. The ...
Sigyn Therapeutics to Present at Tomorrow’s Small Cap Growth Virtual Investor Conference
Learn more about the event at www.virtualinvestorconferences.com.
BioXcel Therapeutics Provides Clinical and Business Update
Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or ...